ASC09F

ASC09/利托那韦

Report date: 2022/08/26 14:15:32
NME

Base Information

Drug NameASC09F
Drug Alias NameASC09/RitonavirASC09F
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsHIV protease inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseHIV protease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes RitonavirTMC-310911
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAscletis Biological Technology (Hangzhou) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTongji Hospital
Inactive CompaniesAscletis Pharma IncAscletis Biological Technology (Hangzhou) Co LtdAscletis Pharmaceutical (Zhejiang) Co Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A